Malaria Advancement Could Shift Investment Perspective on Novartis (SWX:NOVN)

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: Nov 20 2025

0mins

Source: Yahoo Finance

Positive Phase III Results: Novartis announced successful Phase III results for GanLum, a new malaria treatment, highlighting its commitment to addressing global health challenges through innovation.
Investment Outlook: Despite the promising pipeline, Novartis faces risks related to patent expirations and generic competition, particularly for key products like Entresto, which could impact future revenue.
Revenue Projections: Novartis projects $59.1 billion in revenue and $17.3 billion in earnings by 2028, with a focus on maintaining growth amidst potential challenges.
Research and Analysis: The article emphasizes the importance of thorough research and understanding of Novartis' financial health, including potential rewards and risks for investors.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.